Steven Cohen Arcus Biosciences, Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,437,073 shares of RCUS stock, worth $34.8 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
2,437,073
Previous 1,833,851
32.89%
Holding current value
$34.8 Million
Previous $27.9 Million
33.42%
% of portfolio
0.1%
Previous 0.08%
Shares
13 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.7MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$139 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$78.1 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$49.7 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$43 Million0.0% of portfolio
-
Invus Financial Advisors, LLC New York, NY1.61MShares$23 Million27.51% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.03B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...